###### Significance of this study

What is already known about this subject?
=========================================

-   Many studies on mHealth (healthcare delivered via mobile devices) have been conducted---only a few demonstrated beneficial effects

What are the new findings?
==========================

-   The TRIGGER apps provides diabetes self-management education, specifically developed for patients with type 2 diabetes mellitus on insulin therapy.

-   While there were no effects on primary and secondary outcomes, more than half of the users found that receiving the messages motivated them to live healthy.

How might these results change the focus of research or clinical practice?
==========================================================================

-   This study underlines the importance of patient involvement in the development of mHealth applications.

Introduction {#s1}
============

For individuals with type 2 diabetes mellitus, self-management is an essential part of their diabetes treatment, especially for those on insulin therapy. Diabetes self-management is difficult, and healthcare providers are only able to support and stimulate self-management a few times a year.

A solution to provide ongoing diabetes self-management support could be the use of mobile health (mHealth): healthcare delivered via mobile devices. The effectiveness of mHealth as a vehicle for diabetes self-management education and support (DSME/S) has previously been investigated with a great variety of interventions: some trials provided general DSME/S,[@R1] others focused on specific topics such as medication adherence,[@R5] physical activity,[@R7] or insulin titration.[@R8] While some found a statistically significant decrease in HbA1c of approximately 0.6%,[@R2] others did not.[@R1] Only a few studies analyzed the prespecified sample size[@R1]; many studies were underpowered or were pilot studies with small sample size.[@R3] All but two of these trials[@R5] included mostly patients who were not on insulin therapy. Patients on insulin therapy might have differential self-management needs and hence might benefit more from mHealth interventions that are specifically developed for them. Therefore, the aim of this study was to investigate the effect of DSME/S via a smartphone app in individuals with type 2 diabetes on insulin therapy.

Materials and methods {#s2}
=====================

Study design {#s2-1}
------------

We conducted an open two-arm multicenter randomized controlled superiority trial with parallel groups and equal randomization (1:1): 'the TRIGGER study'. For more details, see the study design article.[@R9]

Study population and setting {#s2-2}
----------------------------

Participants were recruited between December 2015 and December 2017 in general practices and hospital outpatient clinics across the Netherlands. Individuals with type 2 diabetes were eligible when they were sufficiently fluent in Dutch, used insulin since ≥3 months, had an HbA1c \>53 mmol/mol (\>7%), were aged 40--70 years, and were treated for their diabetes by the recruiting healthcare provider. Patients were excluded when they had a history of alcoholism, drug abuse, dementia or a major psychiatric disorder. All eligible individuals received an information letter and were recruited by their diabetes care provider. When they agreed to participate, written informed consent was obtained. In primary care, the reasons for not participating, as well as age and sex of those who declined to participate, were recorded.

Intervention {#s2-3}
------------

A smartphone app provided participants with DSME/S delivered as text messages on the following topics: dietary habits, physical activity, prevention of hypoglycemia, and glucose control (including glycemic variability). The text messages were unidirectional and contained specific goals, healthy lifestyle information and challenges, or questions ([online supplementary appendix 1](#SP1){ref-type="supplementary-material"}). Content was based on (inter)national guidelines and on previous mHealth studies. The text messages were critically reviewed by a dietician, physiotherapist, practice nurse and by two individuals with type 2 diabetes on insulin therapy. Messages were framed grammatically correct, free of 'SMS language', benefit oriented, polite, non-aggressive and directive.[@R10] They were in Dutch only. The theory behind the intervention was based on 'behavioural triggers', which play an important role in behavior change.[@R12] A trigger stimulates the individual to engage in health-promoting behavior and can be the last factor to overcome barriers.
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The smartphone app was compatible with iOS and Android operating systems. Users received a push notification when a new text message was available. When users did not open the app during the first 24 hours after a message had been sent, they received a short message service (SMS) reminder. The number of reminder SMS was monitored, as a measurement of compliance. The timing of the messages was either random between 09:30 and 20:00 or at times associated with the content of the message (eg, a text message on dietary habits correlated with traditional mealtimes).

The intervention was tailored, according to patient's preferences:

-   The topics: three or four out of four topics. Hypoglycemia was a mandatory topic, complemented by dietary habits, physical activity, or glucose control.

-   The frequency: two or six times per week, one text message per day.

-   The option to prolong the intervention with another 3 months after the first 6 months. During this period the patients received text messages with unaltered frequency and topics.

Apart from receiving app triggers, the intervention group received care as usual for their type 2 diabetes according to the national diabetes guidelines.[@R16]

Control group {#s2-4}
-------------

Patients randomized to the control group received only care as usual, but were offered the opportunity to use the smartphone app after their follow-up had been completed.

Outcomes {#s2-5}
--------

The primary outcome was the HbA1c level after 6 months in the smartphone app group compared with the control group. As a coprimary outcome we analyzed the proportion of patients who achieved an HbA1c level ≤53 mmol/mol (≤7%) without any hypoglycemic event. Secondary outcomes measured at 6 months were:

-   Body mass index (BMI), blood pressure, lipid profile.

-   Presence of hypoglycemic events.

-   Glycemic variability (since evidence suggests this could be an independent risk factor for diabetes-related complications).[@R17]

-   Self-care behavior (summary of diabetes self-care activities).[@R18]

-   Dietary habits (Kristal's food frequency questionnaire).[@R19]

-   Physical activity (International Physical Activity Questionnaires).[@R20]

-   Health status (EQ-5D-5L questionnaire and visual analog scale, Short Form-36 Health Survey).[@R21]

-   Diabetes-dependent quality of life (Audit of Diabetes-Dependent Quality of Life).[@R23]

-   Diabetes treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire).[@R24]

-   Satisfaction and usability of the app (only intervention group, self-designed questionnaire).

[Online supplementary appendix 2](#SP1){ref-type="supplementary-material"} describes all questionnaires.

Moreover, after 9 months we assessed in the intervention group only: HbA1c, proportion of patients who achieved an HbA1c ≤7% without any hypoglycemic event, BMI and EQ-5D profile.

Data collection {#s2-6}
---------------

Data were collected via online questionnaires, paper patient diaries, and online case report forms. Follow-up measurements overlapped with regular diabetes monitoring visits, usually at three monthly intervals.

At baseline and after 6 months of follow-up, patients completed the online questionnaires; the intervention group also completed one questionnaire after 9 months.

Patients kept a diary in which they recorded any hypoglycemic events during the study. Moreover, once weekly they recorded their fasting plasma glucose, two preprandial values, and bedtime glucose level. Unfortunately, during the study the compliance to the diary proved to be very low. We therefore also evaluated hypoglycemic events by sending participants who did not send back the diary a short questionnaire. If this questionnaire too was not returned, we scrutinized their electronic medical records on any recorded hypoglycemic event.

Practice and diabetes nurses recorded all clinical variables on an online case report form completed at baseline, after 6 months, and for the intervention group also after 9 months of follow-up. BMI and blood pressure were measured according to the standard protocol of the site; HbA1c and lipid profile were assessed by local laboratories.

Sample size {#s2-7}
-----------

Based on the decrease in HbA1c in previous mHealth studies, we expected a mean difference in HbA1c level of 0.41% with an SD of 1.1% between groups after 6 months.[@R25] To detect this difference with an 80% power and an α of 5% after 6 months, 228 patients with type 2 diabetes (114 per treatment group) were needed. We used SAS V.9.4 (SAS) for the sample size calculation.

Randomization, allocation concealment, blinding {#s2-8}
-----------------------------------------------

Patients were individually randomized using simple, fixed block randomization. Randomization was performed centrally at the research center using a web-based computerized random number generator provided by an independent contractor, in the order in which participants were enrolled by their healthcare provider. The randomization allocation was forwarded to the patients approximately 10 days after written informed consent, enabling patients to complete the baseline questionnaires before they knew to which arm they were randomized. Patients were not blinded due to the nature of the intervention.

Changes of methods after trial commencement {#s2-9}
-------------------------------------------

Initially, this study was to be conducted in primary care only. Since recruitment was slower than anticipated, we also recruited patients from hospital outpatient clinics. In the Netherlands, 85% of individuals with type 2 diabetes are treated in primary care; when problems such as persisting inadequate glycemic control occur, patients are referred to hospital outpatient clinics.

As mentioned above, the compliance to the paper patient diary was low. Besides, while we prespecified a hypoglycemic event as plasma glucose \<63 mg/dL (\<3.5 mmol/L), participants reported hypoglycemic events with higher glucose levels. The alternative approaches to assess hypoglycemic episodes---questionnaire and electronic medical record---did not take plasma glucose level into account; hence we decided to accept any self-reported hypoglycemic event irrespective of the plasma glucose level. Since the recall of hypoglycemic events is likely to be more biased compared with keeping a diary, we only evaluated whether or not participants experienced any hypoglycemic event during follow-up, instead of the number of hypoglycemic episodes. Lastly, since waist circumference was missing in more than half of the participants at follow-up, we did not analyze this outcome.

We did not prespecify any sensitivity analyses, but we did perform two (see the Analysis section).

Analysis {#s2-10}
--------

We compared age and sex of the study population to those who declined to participate to assess possible selection. Since the exclusion of participants with missing data can lead to bias, we used multiple imputation to deal with missing data. Characteristics of participants with any missing value for the primary outcome analysis, and those with complete data are shown in [online supplementary appendix 3](#SP1){ref-type="supplementary-material"}, suggesting data are missing at random. We created 10 imputed data sets with 30 iterations under the 'missing at random' assumption.

Participants were analyzed according to the intention-to-treat principle. Continuous outcomes were analyzed with general linear models, binary outcomes with logistic regression. For each outcome, we performed an unadjusted univariable analysis, and a multivariable analysis corrected for age, sex, duration of diabetes, baseline insulin dose, and baseline value of the outcome.

To assess glycemic variability we calculated the coefficient of variation (CoV): the SD divided by the mean \* 100.[@R17]

Because of the large proportion of missing diaries, we did not perform multiple imputation for this outcome and we only present the results of glycemic variability graphically. We performed two sensitivity analyses: (1) in primary care participants, since we designed the app specifically for this population; (2) in those who found that the messages were applicable to them (ie, those who scored \>3 on item 'the messages were applicable to me', scale range: 0--5).

We analyzed the difference between HbA1c, BMI and EQ-5D profile at 9 and 6 months in those who continued using the app compared with those who did not continue with a general linear model corrected for age, sex, duration of diabetes, baseline insulin dose and baseline value.

Answers on the satisfaction and usability of the app questionnaire (continuous scale range: 0--5) were categorized into disagree (\<2), neutral (2--3) and agree (\>3) and were analyzed only for those who completed the questionnaire.

We used RStudio V.1.0.143 for the statistical analyses and mice 3.3.0 package for multiple imputation.

Results {#s3}
=======

Participation, missing data and study population {#s3-1}
------------------------------------------------

Sixty-six general practices and five hospital outpatient clinics recruited 230 participants; of the 66 general practices, 26 were unable to recruit any participant. In primary care, 90 of the 551 individuals who fulfilled the inclusion criteria participated (16.3%, [figure 1](#F1){ref-type="fig"}). In secondary care, 140 participants were included (participation rates per hospital ranging from 9.9% to 17.0%).

![Flow diagram of participants.\*Complete screening information only available from two hospitals†Because of incomplete screening information, only the inclusions from three hospitals are shown‡One participant was excluded from analysis because too little information was available for multiple imputation](bmjdrc-2019-000981f01){#F1}

Information on patients who declined to participate was available of 368 individuals from 48 general practices; the mean age of those who declined to participate was 60.8±8.2 years and 40.2% were women, which is comparable to those who did participate (59.1±7.5 years, 39.1% women). The main reasons for not participating were 'not interested' (38.5%) or 'not owning a smartphone' (30.3%). During follow-up, 17 participants were lost to follow-up ([figure 1](#F1){ref-type="fig"}). For our primary outcome analysis, 4.7% of the values were missing, distributed among 49 participants (21.3%) ([online supplementary appendix 3](#SP1){ref-type="supplementary-material"}). For one participant we were unable to impute missing data.

Mean age was 58.6±8.2 years in the intervention group versus 59.7±6.8 in the control group, 41.7% and 37.4% were women, respectively. [Tables 1 and 2](#T1 T2){ref-type="table"} show more baseline characteristics of our study population. Both groups were well matched.

###### 

Baseline characteristics of the study population (n=230)

  Characteristic, mean (SD) or number (%)   Intervention   Control
  ----------------------------------------- -------------- ------------
  Age (years)                               58.6 (8.2)     59.7 (6.8)
  Sex: female                               48 (41.7)      43 (37.4)
  Educational level                         \*             
   High                                     38 (33.3)      44 (38.3)
   Middle                                   65 (57.0)      62 (53.9)
   Low                                      11 (9.6)       9 (7.8)
  Ethnicity: Caucasian                      92 (80.7)\*    96 (83.5)
  Smoking                                   \*             
   Yes                                      20 (17.5)      21 (18.3)
   Former                                   42 (36.8)      45 (39.1)
   Never                                    52 (45.6)      49 (42.6)
  Diabetes duration (years)                 14.9 (8.3)\*   14.3 (7.7)
  Treatment in secondary care               73 (63.5)      67 (58.3)
  Microvascular complications               65 (57.0)\*    66 (57.4)
  Macrovascular complications               23 (20.2)\*    33 (28.7)
  Injection frequency                       \*             
   Once daily                               37 (32.5)      36 (31.3)
   Twice daily                              6 (5.3)        10 (8.7)
   Four times daily                         63 (55.3)      55 (47.8)
   Other                                    8 (7.0)        14 (12.2)
  Metformin                                 92 (80.7)\*    91 (79.1)
  SU derivatives                            22 (19.3)\*    28 (24.3)
  GLP-1 receptor agonist                    15 (13.2)\*    8 (7.0)
  DPP-4 inhibitors                          2 (1.8)\*      3 (2.6)
  SGLT2 inhibitors                          7 (6.1)\*      5 (4.3)

\*n=114.

DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter 2; SU, sulfonylurea.

###### 

Baseline values and outcomes. Means with their SD, unless otherwise stated

  Outcome                                                                 Baseline       6-month follow-up   Unadjusted difference   95% CI            P value   Adjusted difference   95% CI   P value                         
  ----------------------------------------------------------------------- -------------- ------------------- ----------------------- ----------------- --------- --------------------- -------- --------------- --------------- -------
  **Primary outcomes**                                                                                                                                                                                                          
  HbA1c (%)                                                               8.1 (1.2)      8.3 (1.3)           8.0 (1.6)               8.2 (1.4)         −0.22     −0.57 to 0.13         0.220    −0.08           −0.37 to 0.20   0.557
  HbA1c (mmol/mol)                                                        64.7 (13.2)    66.8 (13.8)         63.8 (17.3)             66.2 (15.7)       −2.41     −6.23 to 1.42         −0.93    −4.02 to 2.17                   
  Number of patients with HbA1c ≤7% (≤53 mmol/mol) without hypoglycemia   n.a.           n.a.                n=10                    n=12              OR 0.85   0.32 to 2.24          0.737    OR 0.87         0.33 to 2.35    0.791
  **Secondary outcomes**                                                                                                                                                                                                        
  Insulin dose (units/kg)                                                 0.72 (0.50)    0.75 (0.52)         0.73 (0.62)             0.71 (0.65)       0.02      −0.12 to 0.16         0.732    0.05            −0.03 to 0.14   0.225
  Hypoglycemic event                                                      n.a.           n.a.                n=58                    n=58              OR 1.02   0.52 to 2.01          0.951    OR 0.99         0.50 to 1.98    0.985
  Body mass index (kg/m^2^)                                               31.4 (5.9)     31.9 (6.1)          31.2 (6.1)              31.8 (6.3)        −0.55     −2.11 to 1.01         0.494    −0.12           −0.72 to 0.47   0.690
  Diastolic blood pressure (mm Hg)                                        78.3 (10.3)    75.6 (10.4)         76.6 (11.9)             76.3 (12.9)       0.34      −2.75 to 3.44         0.828    −0.99           −3.88 to 1.89   0.501
  Systolic blood pressure (mm Hg)                                         135.8 (15.5)   134.4 (15.7)        135.5 (19.9)            137.7 (18.9)      −2.17     −6.97 to 2.64         0.379    −2.60           −7.03 to 1.84   0.253
  Total cholesterol (mmol/L)                                              4.3 (1.0)      4.3 (1.1)           4.5 (2.0)               4.6 (1.7)         −0.07     −0.54 to 0.40         0.772    −0.10           −0.55 to 0.35   0.665
  HDL cholesterol (mmol/L)                                                1.2 (0.4)      1.2 (0.4)           1.2 (0.6)               1.2 (0.5)         −0.05     −0.17 to 0.08         0.453    −0.05           −0.16 to 0.06   0.393
  LDL cholesterol (mmol/L)                                                2.4 (0.9)      2.4 (0.9)           2.5 (1.4)               2.6 (1.6)         −0.07     −0.46 to 0.33         0.734    −0.07           −0.44 to 0.30   0.698
  Triglycerides (mmol/L)                                                  2.4 (1.7)      2.2 (2.1)           2.9 (3.9)               2.7 (3.1)         0.23      −0.67 to 1.12         0.621    0.22            −0.66 to 1.10   0.631
  SDSCA general diet\*                                                    4.6 (1.9)      4.8 (2.1)           4.5 (2.5)               4.7 (2.5)         −0.12     −0.73 to 0.49         0.702    −0.06           −0.61 to 0.50   0.845
  SDSCA high-fat foods\*†                                                 4.1 (2.8)      4.3 (2.5)           4.0 (3.4)               4.4 (3.2)         −0.41     −1.06 to 0.24         0.214    −0.32           −0.94 to 0.30   0.312
  SDSCA fruit and vegetables\*†                                           4.8 (2.4)      5.0 (2.2)           4.5 (2.8)               4.4 (3.2)         0.08      −0.60 to 0.76         0.810    0.18            −0.42 to 0.79   0.553
  SDSCA exercise\*                                                        3.5 (2.4)      3.3 (2.4)           3.5 (3.1)               3.6 (2.8)         −0.13     −0.78 to 0.52         0.694    −0.20           −0.85 to 0.46   0.558
  SDSCA blood sugar testing\*                                             4.3 (2.8)      4.0 (2.9)           4.0 (3.5)               3.6 (3.5)         0.39      −0.33 to 1.11         0.286    0.21            −0.41 to 0.83   0.509
  SDSCA foot care\*                                                       1.8 (2.7)      2.3 (2.9)           1.6 (3.4)               2.3 (3.5)         −0.65     −1.27 to −0.02        0.046    −0.46           −1.03 to 0.11   0.113
  EQ-5D profile‡                                                          0.75 (0.28)    0.78 (0.27)         0.76 (0.37)             0.76 (0.30)       −0.01     −0.09 to 0.07         0.885    0.01            −0.05 to 0.07   0.770
  ADDQoL§                                                                 −1.4 (1.4)     −1.5 (1.5)          −1.6 (1.8)              −1.7 (1.7)        0.07      −0.39 to 0.52         0.771    0.02            −0.33 to 0.38   0.891
  DTSQ total score¶                                                       26.8 (6.2)     26.6 (6.6)          26.3 (8.1)              25.8 (9.5)        0.47      −1.49 to 2.43         0.641    0.42            −1.39 to 2.24   0.649
  DTSQ 2---hyperglycemia\*\*                                              3.2 (1.9)      3.2 (1.9)           3.1 (3.1)               3.1 (3.3)         0.04      −0.56 to 0.64         0.900    0.06            −0.52 to 0.63   0.850
  DTSQ 3---hypoglycemia\*\*                                               1.7 (1.7)      1.5 (1.8)           1.7 (2.6)               2.0 (3.1)         −0.26     −0.90 to 0.38         0.431    −0.30           −0.98 to 0.37   0.378
  Healthy diet score††                                                    41.1 (11.4)    43.4 (11.9)         41.3 (14.2)             42.1 (11.9)       −0.82     −3.82 to 2.17         0.591    0.22            −2.66 to 3.11   0.881
  MET-minutes                                                             7647 (731)     9078 (756)          12 607 (18 923)         13 589 (18 104)   −982      −5225 to 3260         0.652    −56             −3944 to 3832   0.978
  SF-36 PCS‡‡                                                             43.8 (13.7)    42.5 (13.8)         43.3 (17.5)             42.1 (16.8)       1.24      −3.17 to 5.65         0.586    0.30            −3.51 to 4.12   0.877
  SF-36 MCS‡‡                                                             49.1 (12.6)    50.1 (12.2)         49.4 (13.2)             49.5 (17.3)       − 0.03    −3.47 to 3.40         0.985    0.63            −2.57 to 3.83   0.702

\*Score range: 0--7.

†Cronbach's alpha was too low to compute the total score for these two domains.

‡Score range: −0.44 to 1.00.

§Score range: −9 to +3.

¶Score range: 0 to 36.

\*\*Score range: 0--6.

††Score range: 0--70.

‡‡Score range: 0--100.

ADDQoL, Audit of Diabetes-Dependent Quality of Life; DTSQ, Diabetes Treatment Satisfaction Questionnaire; EQ-5D, EuroQoL-5 Dimension; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCS, Mental Health Component Summary Score; MET, metabolic equivalent; n.a., not applicable; PCS, Physical Component Summary Score; SDSCA, summary of diabetes self-care activities; SF-36, Short Form-36 Health Survey.

App preferences {#s3-2}
---------------

Most patients chose to receive two messages weekly; only 38 participants (33%) chose to receive six messages weekly. Almost half of the participants chose all four categories of messages, while 64 participants (55.7%) chose three categories. Dietary habits were most often chosen (86.1%), followed by glucose control (83.5%); least often chosen was physical activity (74.8%).

Primary outcomes {#s3-3}
----------------

At follow-up, the HbA1c level was slightly lower in the intervention group in both the unadjusted and the adjusted analysis, but this difference was not statistically significant ([table 2](#T2){ref-type="table"}). The odds for achieving an HbA1c level ≤53 mmol/mol (≤7%) without any hypoglycemic event was marginally lower in the intervention group, but this difference was also not statistically significant ([table 2](#T2){ref-type="table"}). The sensitivity analyses among primary care participants resulted in a larger adjusted mean HbA1c difference of −2.21 mmol/mol (−0.20%), p=0.403 ([online supplementary appendix 4](#SP1){ref-type="supplementary-material"}). When restricting the analysis to those who found messages applicable to them, the adjusted mean HbA1c difference was −2.40 mmol/mol (−0.22%), p=0.231 ([online supplementary appendix 4](#SP1){ref-type="supplementary-material"}).

Secondary outcomes {#s3-4}
------------------

At follow-up, there were no statistically significant differences between the intervention and control group in any of the secondary outcomes ([table 2](#T2){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} shows the glycemic variability over 6 months, expressed as CoV of those who completed the diary.

![Glycemic variability expressed as coefficient of variation (CoV, percentage) with 95% CI (n minimum=45 (week 1); n maximum=69 (week 15)).](bmjdrc-2019-000981f02){#F2}

Safety, compliance, technical issues and satisfaction with the app {#s3-5}
------------------------------------------------------------------

No adverse events were reported. During the trial, all but one participant received at least one reminder SMS. The median number of reminder SMS sent was 20 (range 1--123). We received 26 notifications regarding technical issues such as being unable to find the app, not able to download the app, unable to register the app or accidently having deleted the app. Of 115 participants randomized to the control group, 13 registered the app after the trial had finished. [Table 3](#T3){ref-type="table"} shows the results of the applicability and usability of the app: 61.0% found that receiving the messages motivated them to live healthy; 44.4% found the messages applicable to them.

###### 

Satisfaction with and applicability of the app (disagree: \<2; neutral: 2--3; agree: \>3; on a continuous scale, range 0--5)

                                                                                      n    Disagree (%)   Neutral (%)   Agree (%)
  ----------------------------------------------------------------------------------- ---- -------------- ------------- -----------
  Receiving the messages motivated me to live healthy.                                82   19.5           19.5          61.0
  Receiving the messages taught me a lot about diabetes.                              81   21.0           27.2          51.9
  The messages were sent at the right moments.                                        81   13.6           25.9          60.5
  The information in the messages was difficult to understand.                        81   71.6           4.9           23.5
  If I were to proceed with the program I would want to receive fewer messages.       81   38.3           14.8          46.9
  I would recommend this application to family and friends with diabetes.             81   25.9           13.6          60.5
  The messages prompted me to improve the healthiness of my diet.                     80   42.5           20.0          37.5
  The messages encouraged me to exercise more.                                        81   43.2           19.8          37.0
  Because of the messages, I am more capable of dealing with hypoglycemia.            80   47.5           16.3          36.3
  The messages were applicable to me.                                                 81   28.4           27.2          44.4
  I often made use of the messages (eg, I took the stairs or cooked a healthy meal)   81   33.3           23.5          43.2
  I often forgot to make use of the messages                                          81   35.8           13.6          50.6

Cost-effectiveness {#s3-6}
------------------

We did not perform the prespecified cost-effectiveness analysis,[@R9] since it seemed to be redundant based on the absence of any effects, and on similar healthcare resource usage between the groups.

Prolonged follow-up {#s3-7}
-------------------

Of the 115 participants randomized to the intervention group, 24 prolonged the intervention with another 3 months. In those who continued using the app, the HbA1c after 9 months was 0.52 mmol/mol (0.05%) lower compared with the level at 6 months. In those who did not continue using the app, the HbA1c after 9 months remained equal to the level at 6 months. The odds for achieving an HbA1c level ≤53 mmol/mol (≤7%) without any hypoglycemic event did not alter in the period between 6 and 9 months, nor were there differences in BMI and EQ-5D profile (data not shown).

Discussion {#s4}
==========

Summary of main findings {#s4-1}
------------------------

This trial investigated the effect of DSME/S via a smartphone app in individuals with type 2 diabetes on insulin therapy. The effects were absent or marginal and not clinically relevant. Participants rated the applicability and usability of the app quite diverse: approximately as many participants found that receiving the messages motivated them to live healthy, as found the opposite. More than half of participants did not find the messages applicable to them, and often forgot to make use of them.

Interpretation {#s4-2}
--------------

The overall participation rate in this mHealth trial was 9.9%--17.0%. A qualitative study found that patients with diabetes (compared with chronic obstructive pulmonary disease and cardiovascular diseases) were most willing to use eHealth.[@R27] Nevertheless, like other mHealth trials we experienced problems with recruiting participants.[@R28] In 2016 almost 90% of the Dutch population aged 45--65 years had access to a mobile phone with internet capacity, but for those above 65 years this was only 50%.[@R30] Approximately one-third of those who were asked to participate in our trial said they did not own a smartphone. We probably overestimated the proportion of patients with a smartphone. Moreover, since self-management interventions are not 'one-size-fits-all',[@R31] many of those who were asked to participate simply could not have wanted to use mHealth. This 'one-size-does-not-fit-all' concept is supported by the fact that two-thirds of our participants chose the least intensive frequency, and more than half of the participants chose three instead of four topics.

The sensitivity analysis among those who found messages applicable to them suggests that the intervention might be more effective in this group. While this is something one might expect, it shows that---with an overall lack of effectiveness---for subgroups this app could be useful, surely when we take into account that self-management interventions should be personalized.[@R31] We chose to perform one sensitivity analysis among those who found the messages applicable. We could have performed 12 sensitivity analyses for each question, thereby identifying a subgroup of participants for whom the app works best. This (data-driven analysis) was however beyond the scope of this research.

While we involved patients with type 2 diabetes in critically reviewing the content of the messages, we did not involve patients in earlier stages of the design of the intervention and the trial. We therefore could have misinterpreted the participants' needs, which is supported by the fact that most participants did not find the messages applicable to them. We made an attempt to personalize the messages by enabling participants to choose the frequency and topics, but the low proportion of participants who found the messages applicable shows that this was not personalized enough. We initially designed the intervention for patients with type 2 diabetes treated in primary care, but ended up with the majority of participants recruited from outpatient clinics of hospitals. The sensitivity analysis suggested that the effect of the intervention on the HbA1c level was larger in the primary care participants. In the Netherlands, patients treated at hospital outpatient clinics have previously been treated in primary care. For these patients, who have received diabetes education from the practice nurse, general practitioner, diabetes nurse and endocrinologist, additional basic DSME/S via an app likely does not add anything new to their knowledge, abilities and skills. The theory behind the intervention was based on 'behavioural triggers'. While a trigger can prompt individuals to engage in health-promoting behavior, individuals need to have a certain level of ability and motivation for the trigger to work.[@R12]

Comparison with literature {#s4-3}
--------------------------

A trial conducted in Bangladesh investigated a similar intervention: DSME sent via SMS for 6 months.[@R2] In this trial the intervention effectively lowered the HbA1c level in the intervention group. The patients included in this trial, however, could hardly be more different from our population: their median diabetes duration was 1 year and none of them used insulin. Evidently, the trial was conducted in a lower middle-income country and moreover their population only had received 9 years of education (unpublished data). Our study population was relatively highly educated compared with the general Dutch type 2 diabetes population.[@R32] These highly educated patients could also benefit less from DSME/S.

Study strengths and limitations {#s4-4}
-------------------------------

While age and sex of those who declined to participate were similar to those who participated, our participants were different compared with a previous European population on insulin therapy.[@R33] Our population was younger, but with a longer diabetes duration and more microvascular complications. Moreover, our study population had a higher HbA1c level and was less satisfied with the diabetes treatment.[@R33] These differences can be explained by our inclusion criteria, which may have resulted in a study population that had been using insulin for many years, but still fails to reach good glycemic control and is less satisfied with the treatment. Hence, our results may not be fully generalizable to all people with type 2 diabetes who use insulin. Another limitation is that we did not monitor the use of other diabetes apps. Participants randomized to the control arm could have downloaded another diabetes app, which could have biased our results towards null. As mentioned earlier, the app was intended for individuals treated in primary care; moreover we hypothesized that the app would be especially suited for individuals with a low socioeconomic status.[@R9] Nevertheless, we included mainly secondary care patients, and those with a high educational level.

Strengths of this trial are the large sample size and the statistical analysis in which we corrected for prognostic determinants. Moreover, we only included people with type 2 diabetes, while other trials have included both type 1 and type 2 diabetes[@R5]; one trial found an overall beneficial effect of mHealth, but in the subgroup restricted to type 2 diabetes no statistically significant effects were found.[@R34]

Implications {#s4-5}
------------

This study shows that our theory and evidence-based mHealth intervention was not effective, probably because it was not designed 'bottom up' and not enough personalized. To be effective, apps should optimally incorporate the needs of end-users. While in our trial participants could choose the frequency of and topics of the intervention, future interventions should target specific populations taking into account their needs and expectations.
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